|
||
J. Exp. Med.,
Volume 189, Number 2, January 18, 1999 395-402
By

From the * Laboratory of Molecular Immunoregulation, Division of Basic Sciences; the We have previously reported (Badolato, R., J.M. Wang, W.J. Murphy, A.R. Lloyd, D.F.
Michiel, L.L. Bausserman, D.J. Kelvin, and J.J. Oppenheim. 1994. J. Exp. Med. 180:203; Xu,
L., R. Badolato, W.J. Murphy, D.L. Longo, M. Anver, S. Hale, J.J. Oppenheim, and J.M.
Wang. 1995. J. Immunol. 155:1184.) that the acute phase protein serum amyloid A (SAA) is a
potent chemoattractant for human leukocytes in vitro and mouse phagocytes in vivo. To identify the signaling mechanisms, we evaluated patterns of cross-desensitization between SAA and
other leukocyte chemoattrctants. We found that the chemotactic bacterial peptide, N-formyl-
methionyl-leucyl-phenylalanine (fMLP), was able to specifically attenuate Ca2+ mobilization in
human phagocytes induced by SAA, but only at very high concentrations, suggesting that SAA
uses a low affinity fMLP receptor. Here we demonstrate that SAA selectively induced Ca2+
mobilization and migration of HEK cells expressing FPRL1, a human seven-transmembrane
domain phagocyte receptor with low affinity for fMLP, and high affinity for lipoxin A4. Furthermore, radiolabeled SAA specifically bound to human phagocytes and FPRL1-transfected 293 cells. In contrast, SAA was not a ligand or agonist for FPR, the high affinity fMLP receptor. Thus, SAA is the first chemotactic ligand identified for FPRL1. Our results suggest that
FPRL1 mediates phagocyte migration in response to SAA.
Intramural
Research Support Program, SAIC Frederick, National Cancer Institute-Frederick Cancer Research
and Development Center, Frederick, Maryland 21702-1201; and the § Laboratory of Host Defenses,
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,
Maryland 20892
This article has been cited by other articles:
| TABLE OF CONTENTS |
|